Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Interventions for smoking cessation in people diagnosed with lung cancerInterventions for smoking cessation in people diagnosed with lung cancerFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerNew targeted treatments for non-small-cell lung cancer - role of nivolumabOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerc-Met as a Target for Personalized TherapyThe Evolution of Therapies in Non-Small Cell Lung CancerEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidencePemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)MicroRNA Profiling of the Effect of the Heptapeptide Angiotensin-(1-7) in A549 Lung Tumor Cells Reveals a Role for miRNA149-3p in Cellular Migration ProcessesConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature reviewFirst-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Prognostic impact of M descriptors of the 8th edition of TNM classification of lung cancer.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapyModulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatinThe efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisChemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.
P2860
Q24187218-E2594CEB-9C81-40BA-9EBD-1678C4DD5E65Q24187486-1EA72A53-DCCE-4FD6-BABC-B691A7B6392AQ26471909-6B9BDCBF-BA54-4FC7-9A05-DB3D4D3A46FAQ26740988-6AE3A500-73EC-428E-BA40-593AC3C10DF1Q26745427-E46595A7-4F3D-412C-BE6F-42744A1E116BQ26745776-B2EDA715-EB9F-4E94-AC70-049566643DECQ26771116-A32DCF6F-CEDB-4D74-9441-5B57BE0E3512Q26775376-7B220BA2-92C7-46E6-AB88-8CFB78CFED71Q26775483-436765F6-DE6C-4074-AFD4-EBC173F82CE8Q26786932-06669C3E-1078-4372-A4F4-916E7038C160Q26995204-224B3250-193A-4666-8138-1DE8ED529104Q27027957-870232D9-09CC-4931-ADD4-5CFBD081B8F7Q28067196-61C1CB60-341C-4E65-816A-BE6AFC6F7FCBQ28067306-77ED4822-F756-42ED-A345-8B63F292C82CQ28073920-C721F4AE-34E8-430E-931C-2199DEAC6F02Q28074716-A9D7242A-DDFC-4A73-92DC-E2E4C2A90F53Q28075291-5D0E33C1-E16A-4B54-8CCB-F11322D92504Q28079320-5ED586D6-105A-4E6A-9150-D5CC9FF51B4BQ28081243-82208812-A110-494C-957E-53F12292102BQ28388692-EBB53663-9204-4A2A-BE4B-78FA338C1080Q30234436-510DDA6C-1F12-4B0A-895E-0D4D8E26E4A8Q31121041-AE138875-D427-463B-994B-E1B1B713B44CQ31133861-369C3BEC-7480-4753-BFB0-325C1C0540ADQ33426444-C978F74C-9AFA-4048-A21C-1F4ED1882ABFQ33427359-C6DB6E2F-1456-4B0E-A078-C9FF7D40E5A3Q33432898-2B37AD35-B24A-41A7-9CEC-CC0455F967C0Q33439970-6D90635B-96D5-4296-849D-CC5DD984466BQ33439985-425A7017-223B-4C1A-8E3B-848F53F39463Q33571340-1090E6B9-B46C-4E07-B0A1-916662C823DAQ33648808-F9D247C5-B9DC-4FFE-BC76-0A050360AB13Q33690682-7C044D8B-0C29-421B-AA6A-3C715357B4DCQ33738921-FA807D11-66C3-4604-B559-FCC90E50E192Q33868401-9AD1D0CB-FE03-45C8-9DD0-1E44F3936A7AQ34452186-EFD80C93-0BBA-45B8-8DF7-8B1B0A6BA3AEQ35397008-8593A3EE-9C78-4D75-B27F-31DA15AB4E8CQ35584008-31F4AFC2-2511-405E-A9EE-F1B3AE37D0D5Q35649624-F0771370-D288-4AE7-8707-B51CD310A43FQ35683412-A7CBC60E-FAF7-4052-B099-3F26037889D9Q35872968-6735BAD3-5E90-4474-A9C1-BF2FB43EB236Q36093612-3C9D565A-8F16-4B34-B0B2-77CCFADD0AF9
P2860
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@ast
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@en
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@nl
type
label
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@ast
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@en
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@nl
prefLabel
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@ast
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@en
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Metastatic non-small-cell lung ...... osis, treatment and follow-up.
@en
P2093
D De Ruysscher
ESMO Guidelines Working Group
N Reinmuth
P2860
P304
P356
10.1093/ANNONC/MDU199
P478
25 Suppl 3
P50
P577
2014-08-11T00:00:00Z